BioMarin Nederland

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. In early 2015, BioMarin acquired Prosensa and added multiple potential products to treat Duchenne Muscular Dystrophy (DMD), including drisapersen, an investigational therapy for the largest genetically defined subgroup of this patient population.